Search
Immunome Inc
IMNMAdd to Watchlist
18.770USD
+0.070+0.37%
Close 11-13 16:00（ET）
2.21BMarket Cap
LossP/E TTM
Immunome Inc (IMNM) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to Immunome Inc in the past month.
Buy
4 Strong Buy
12 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
33.664USD+84.86%
IMNM Analyst Recommendation Trends
In the current month, IMNM has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the last month is 33.664.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
3
3
4
4
4
4
12
12
11
11
11
10
10
10
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
17
14
14
15
14
14
14
IMNM Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, IMNM EPS is projected to reach -0.653 in FY2026Q4, following reported EPS of -0.755 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.56
-0.52
-0.63
-0.65
-0.71
Actual
-0.48
-0.65
-0.76
--
--
Surprise
+15.37%
-23.64%
-19.85%
--
--
FAQs
What is Immunome Inc's expected revenue for the next quarter?
Immunome Inc's expected revenue is 142.86K.
What is Immunome Inc's price target?
Analysts forecast that Immunome Inc's price target is USD 34.93, with the highest forecast at USD 40.00 and the lowest forecast at USD 24.00.
How have Immunome IncIMNM's recent earnings per share performed?
The market expectation was USD -0.76, while Immunome IncIMNM's earnings per share (EPS) for the previous quarter was USD -0.65. EPS for the next quarter is expected at USD -0.65.
What is the analyst rating for Immunome Inc?
Based on the ratings of Immunome Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.